NextPoint Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Labcentral 238 Main Cambridge Massachuse...Phone Number
(508) 204-1115Website
www.nextpointtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About NextPoint Therapeutics
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.Explore more
NextPoint Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NextPoint Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once NextPoint Therapeutics has new funding data
Product Launch: Get notified when NextPoint Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at NextPoint Therapeutics
Check out if NextPoint Therapeutics is spiking on competitors!
Click to see if NextPoint Therapeutics had a recent Job posting/layoffs
Check if NextPoint Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on NextPoint Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
NextPoint Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to NextPoint Therapeutics
Compare insights from companies similar to NextPoint Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NextPoint Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NextPoint Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NextPoint Therapeutics.
NextPoint Therapeutics financials insights
Gather financial insights about NextPoint Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$80M
2024
Series B
$42.5M
NextPoint Therapeutics Tech Stack
A closer look at the technologies used by NextPoint Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Person-Based
Funding
Funding
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding NextPoint Therapeutics
Sign Up For FreeTo access detailed company insights
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simulta... Read More
